Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the immunogenicity and safety of a Sabin inactivated poliovirus vaccine (sIPV) given in a 1+2 schedule with bOPV in infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• bOPV (bivalent oral polio vaccine)
• sIPV (Sabin inactivated polio vaccine)

Snippet

Sponsor: Sinovac Biotech Co., Ltd | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED